Timothy D. Shu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Timothy D. Shu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Sarah C. Markt
CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA
2 shared publications- Aatur D. Singhi
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
1 shared publication - Adam C. Calaway
Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
1 shared publication Adam Calaway
Urology Institute, University Hospitals Cleveland Medical Center, Cleveland, USA
1 shared publication- Alberto Andres Castro Bigalli
Division of Urology and Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
1 shared publication - Alessandro Paniccia
Division of GI Surgical Oncology, UPMC Pancreatic Cancer Center, University of Pittsburgh Medical Center, UPMC Cancer Pavilion, Pittsburgh, USA
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (5) , 731-737
Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes
- 22 May 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (5) , 731-737
Open AccessCigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes
- 8 March 2023
- Published by Springer Nature in Cancer Causes & Control
- Vol. 34 (6) , 521-531
Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database
Purpose Previous literature shows that more bladder cancer patients overall die from causes other than the primary malignancy. Given known disparities in bladder cancer outcomes by race and sex, we aimed to characterize differences in cause-specific mortality for bladder cancer patients by these demographics. Methods We identified 215,252 bladder cancer patients diagnosed with bladder cancer from 2000 to 2017 in the SEER 18 database. We calculated cumulative incidence of death from seven causes (bladder cancer, COPD, diabetes, heart disease, external, other cancer, other) to assess differences in cause-specific mortality between race and sex subgroups. We used multivariable Cox proportional hazards regression and Fine-Gray competing risk models to compare risk of bladder cancer-specific mortality between race and sex subgroups overall and stratified by cancer stage. Results 17% of patients died from bladder cancer (n = 36,923), 30% died from other causes (n = 65,076), and 53% were alive (n = 113,253). Among those who died, the most common cause of death was bladder cancer, followed by other cancer and diseases of the heart. All race-sex subgroups were more likely than white men to die from bladder cancer. Compared to white men, white women (HR: 1.20, 95% CI: 1.17–1.23) and Black women (HR: 1.57, 95% CI: 1.49–1.66) had a higher risk of dying from bladder cancer, overall and stratified by stage. Conclusion Among bladder cancer patients, death from other causes especially other cancer and heart disease contributed a large proportion of mortality. We found differences in cause-specific mortality by race-sex subgroups, with Black women having a particularly high risk of dying from bladder cancer.
- 8 March 2023
- Published by Springer Nature in Cancer Causes & Control
- Vol. 34 (6) , 521-531
Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database
Purpose Previous literature shows that more bladder cancer patients overall die from causes other than the primary malignancy. Given known disparities in bladder cancer outcomes by race and sex, we aimed to characterize differences in cause-specific mortality for bladder cancer patients by these demographics. Methods We identified 215,252 bladder cancer patients diagnosed with bladder cancer from 2000 to 2017 in the SEER 18 database. We calculated cumulative incidence of death from seven causes (bladder cancer, COPD, diabetes, heart disease, external, other cancer, other) to assess differences in cause-specific mortality between race and sex subgroups. We used multivariable Cox proportional hazards regression and Fine-Gray competing risk models to compare risk of bladder cancer-specific mortality between race and sex subgroups overall and stratified by cancer stage. Results 17% of patients died from bladder cancer (n = 36,923), 30% died from other causes (n = 65,076), and 53% were alive (n = 113,253). Among those who died, the most common cause of death was bladder cancer, followed by other cancer and diseases of the heart. All race-sex subgroups were more likely than white men to die from bladder cancer. Compared to white men, white women (HR: 1.20, 95% CI: 1.17–1.23) and Black women (HR: 1.57, 95% CI: 1.49–1.66) had a higher risk of dying from bladder cancer, overall and stratified by stage. Conclusion Among bladder cancer patients, death from other causes especially other cancer and heart disease contributed a large proportion of mortality. We found differences in cause-specific mortality by race-sex subgroups, with Black women having a particularly high risk of dying from bladder cancer.
- 1 January 2023
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 10 (1) , 59-65
Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65
Introduction:Medicare eligibility at 65 has been associated with increased diagnosis and survival for certain cancers due to greater health care utilization. We aim to assess for a similar ...
- 1 January 2023
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 10 (1) , 59-65
Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65
Introduction:Medicare eligibility at 65 has been associated with increased diagnosis and survival for certain cancers due to greater health care utilization. We aim to assess for a similar ...
- Open Access
- 18 August 2022
- Published by Elsevier in Urology Case Reports
- Vol. 45, 102188
Duplex renal collecting system presenting with hydroureteronephrosis following pelvic organ prolapse and sacrocolpopexy in an adult female
- 18 August 2022
- Published by Elsevier in Urology Case Reports
- Vol. 45, 102188
Open AccessDuplex renal collecting system presenting with hydroureteronephrosis following pelvic organ prolapse and sacrocolpopexy in an adult female